Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

42.48USD
21 Feb 2017
Change (% chg)

$-0.68 (-1.58%)
Prev Close
$43.16
Open
$42.21
Day's High
$42.52
Day's Low
$42.08
Volume
1,706,744
Avg. Vol
2,166,678
52-wk High
$44.50
52-wk Low
$36.81

Latest Key Developments (Source: Significant Developments)

Myokardia says Sanofi has notified company that it has elected to continue global cardiomyopathy research collaboration
Tuesday, 3 Jan 2017 08:30am EST 

Myokardia Inc : Myokardia Inc - Sanofi has notified company that it has elected to continue global cardiomyopathy research collaboration formed in August 2014 . Myokardia Inc - Myokardia is now eligible for a $45 million milestone payment payable by January 31, 2017. .Myokardia Inc - intends to initiate a phase 1 study of MYK-491 in healthy volunteers in first half of 2017..  Full Article

Sanofi in advanced talks to buy Actelion- Bloomberg, citing sources
Thursday, 15 Dec 2016 08:43pm EST 

:Sanofi said to be in advanced talks to buy drugmaker Actelion, companies discussing price of about $275 per actelion share- bloomberg, citing sources.  Full Article

Sanofi to explore counterbid for Actelion amid J&J talks - Bloomberg, citing sources
Monday, 5 Dec 2016 04:25pm EST 

:Sanofi to explore counterbid for Actelion amid J&J talks - Bloomberg, citing sources.  Full Article

Sanofi Genzyme says initiation of ICARIA-MM phase III trial of Isatuximab
Monday, 5 Dec 2016 12:50pm EST 

Sanofi Genzyme :Initiation of ICARIA-MM phase III trial of Isatuximab.  Full Article

China Resources Sanjiu Medical & Pharma plans framework agreement with Sanofi
Thursday, 1 Dec 2016 11:20pm EST 

China Resources Sanjiu Medical & Pharmaceutical Co Ltd <000999.SZ> : Says it plans to sign framework agreement with Sanofi SA on consumer health business .Says it plans to set up JV in China with Sanofi's unit.  Full Article

Natrix Separations announces collaboration agreements with Merck and Sanofi
Wednesday, 30 Nov 2016 09:30am EST 

Natrix Separations Inc : PRESS RELEASE - Natrix Separations announces collaboration agreements with Merck and Sanofi for the development of membrane-based Protein A purification platform . development agreements with Merck, Sanofi to advance Natrix's new membrane-based Protein A platform for antibody purification . specific financial terms were not disclosed .deal with SCIL Proteins Gmbh for engineering, development of proprietary Protein A ligand to be integrated with co's membrane technology.  Full Article

Sanofi says receives FDA approval of Soliqua 100/33
Monday, 21 Nov 2016 07:06pm EST 

Sanofi Sa : Sanofi receives FDA approval of Soliqua(tm) 100/33, for the treatment of adults with type 2 diabetes .Says Soliqua 100/33 will be available in U.S. retail pharmacies in January 2017.  Full Article

Sanofi says receives FDA approval of Soliqua 100/33
Monday, 21 Nov 2016 06:20pm EST 

Sanofi Sa : Sanofi receives FDA approval of Soliqua(tm) 100/33, for the treatment of adults with type 2 diabetes .Says Soliqua 100/33 will be available in U.S. retail pharmacies in January 2017.  Full Article

Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting
Wednesday, 16 Nov 2016 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals-In MONARCH study, sarilumab monotherapy showed superiority over adalimumab monotherapy in adults with active rheumatoid arthritis .Press Release - Regeneron and Sanofi present results from phase 3 MONARCH study of investigational sarilumab at American College of Rheumatology Annual Meeting.  Full Article

Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision
Monday, 14 Nov 2016 08:00am EST 

Alnylam Pharmaceuticals Inc : Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders . Sanofi genzyme elects not to opt in for ALN-AS1 in acute hepatic porphyrias . Alnylam intends to commercialize ALN-AS1 globally upon product approval . Co, Sanofi Genzyme will co-develop and co-commercialize fitusiran in U.S., Canada, Western Europe . Alnylam pharma - Sanofi Genzyme will be required to make payments up to $75 million upon achievesanment of development, regulatory milestones for fitusiran .On track to initiate fitusiran Phase 3 program in early 2017.  Full Article

More From Around the Web

Photo

How Sanofi lost out to J&J in $30 billion battle for Actelion

ZURICH Swiss biotech company Actelion , days before agreeing to a $30 billion bid by Johnson & Johnson , found a rival offer to be as attractive but went with J&J because its offer provided more certainty, a filing showed on Thursday.